Eptinezumab Anti-CGRP monoclonal antibody Treatment of migraine

被引：0

作者：

Lu, Lingyun ^{[1
]}

Liu, Meijun ^{[2
]}

Hu, Songshan ^{[1
]}

Liu, Yao ^{[3
]}

Yang, Dongdong ^{[2
]}

Hong, Peiwei ^{[4
]}

机构：

[1] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China

[2] Chengdu Univ Tradit Chinese Med, Affiliated Hosp 1, Chengdu, Sichuan, Peoples R China

[3] Xindu Hosp Tradit Chinese Med, Chengdu, Sichuan, Peoples R China

[4] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China

来源：

DRUGS OF THE FUTURE | 2017年 / 42卷 / 10期

关键词：

Eptinezumab; ALD-403; Anti-CGRP; Antimigraine drugs; GENE-RELATED PEPTIDE; RANDOMIZED CONTROLLED-TRIAL; RECEPTOR ANTAGONIST; DOUBLE-BLIND; PREVENTIVE TREATMENT; EPISODIC MIGRAINE; TELCAGEPANT; EFFICACY; SAFETY; TOLERABILITY;

D O I：

10.1358/dof.2017.042.10.2701433

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Eptinezumab (ALD-403) is a genetically engineered, humanized, desialylated anti-calcitonin gene-related peptide (CGRP) IgG1 monoclonal antibody that selectively binds to both a and beta forms of human CGRP, which is a promising therapeutic target for migraine. Pharmacokinetic data indicated that monthly dosing of an intravenous eptinezumab infusion could maintain bioactive levels and blood concentration for a long time. Phase I and II studies evaluating the safety and efficacy of eptinezumab in episodic and chronic migraine were completed with encouraging results, and there are currently three large phase III studies ongoing. This review summarizes the clinical trials already conducted or ongoing and the initial findings regarding the safety and efficacy of eptinezumab for the treatment of migraine.

引用

页码：609 / 615

页数：7

共 50 条

[21] Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine
Iannone, Luigi Francesco
De Cesaris, Francesco
Ferrari, Anita
Benemei, Silvia
Fattori, Davide
Chiarugi, Alberto
[J]. CEPHALALGIA, 2022, 42 (13) : 1323 - 1330
[22] HOW MUCH OF ANTI-CGRP MONOCLONAL ANTIBODY PREVENTIVE THERAPY FOR MIGRAINE IS CONTEXTUAL (PLACEBO) EFFECT?
Forbes, Raeburn B.
McCarron, Mark O.
[J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (12): : E13 - E13
[23] DO MULTIPLE TREATMENT CYCLES WITH ANTI-CGRP MONOCLONAL ANTIBODIES MODIFY MIGRAINE COURSE?
Aurilia, C.
Egeo, G.
Proietti, S.
Torelli, P.
Cevoli, S.
D'Onofrio, F.
Bonassi, S.
Barbanti, P.
[J]. HEADACHE, 2023, 63 : 126 - 126
[24] Anti-CGRP Monoclonal Antibodies for the Treatment of Migraine with Aura: a prospective observational cohort study
Braca, S.
Russo, C.
Miele, A.
Stornaiuolo, A.
Sansone, M.
De Simone, R.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 376 - 376
[25] New Anti-CGRP Medications in the Treatment of Vestibular Migraine
Hoskin, Justin L.
Fife, Terry D.
[J]. FRONTIERS IN NEUROLOGY, 2022, 12
[26] Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
Pellesi, Lanfranco
Guerzoni, Simona
Pini, Luigi Alberto
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (06): : 534 - 547
[27] Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention
Carlo Lovati
Gianna Bernasconi
Chiara Capogrosso
Laura Molteni
Federica Giorgetti
Bernardo Dell’Osso
Leonardo Pantoni
[J]. Neurological Sciences, 2022, 43 : 5765 - 5767
[28] Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention
Lovati, Carlo
Bernasconi, Gianna
Capogrosso, Chiara
Molteni, Laura
Giorgetti, Federica
Dell'Osso, Bernardo
Pantoni, Leonardo
[J]. NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5765 - 5767
[29] Anti-CGRP monoclonal antibodies: migraine prevention in patients with psychiatric comorbidities
di Cola, Francesca Schiano
Ceccardi, Giulia
Caratozzolo, Salvatore
Bolchini, Marco
Di Pasquale, Michele
Rao, Renata
Padovani, Alessandro
[J]. CEPHALALGIA, 2023, 43 (1supp) : 252 - 253
[30] Anti-CGRP Monoclonal Antibodies for Neuropathic Pain in Patients with Migraine Headache
Kang, Seung Ah
Govindarajan, Raghav
[J]. NEUROLOGY, 2021, 96 (15)

← 1 2 3 4 5 →